InvestorsHub Logo
Followers 466
Posts 26939
Boards Moderated 2
Alias Born 09/11/2006

Re: None

Friday, 06/18/2010 8:26:53 AM

Friday, June 18, 2010 8:26:53 AM

Post# of 69
Positive Phase 2 Data on RDEA594, Ardea Biosciences' Lead Product Candidate for the Treatment of Hyperuricemia and Gout, Presented at the Annual European Congress of Rheumatology
New Data from Five Clinical Studies Reinforce RDEA594's Robust Efficacy and Encouraging Safety

http://finance.yahoo.com/news/Positive-Phase-2-Data-on-prnews-286652561.html?x=0&.v=1


surf's up......crikey